Domperidone

Pharmacologic Category

Dopamine Antagonist; Gastrointestinal Agent, Prokinetic

Dosing: Adult

GI motility disorders (diabetic gastroparesis, gastritis), Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents: Oral: 10 mg 3 times daily (maximum: 30 mg/day). Use the lowest effective dose for the shortest duration necessary. For gastroparesis, the American College of Gastroenterology recommends initiating at 10 mg 3 times daily (Camilleri 2013).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer’s labeling; however, depending on severity of impairment, frequency should be reduced to 1 to 2 times daily and dosage reduction considered with repeated administration.

Dosing: Hepatic Impairment: Adult

Mild impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution (undergoes hepatic metabolism).

Moderate or severe impairment: Use is contraindicated.

Use: Labeled Indications

Note: Not approved in the US

GI motility disorders: Symptomatic management of upper GI motility disorders associated with chronic and subacute gastritis and diabetic gastroparesis

Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents: Prevention of GI symptoms (eg, nausea, vomiting) associated with use of dopamine-agonist anti-Parkinson agents

Clinical Practice Guidelines

Dyspepsia:

ACG/CAG “Guidelines for the Management of Dyspepsia,” June 2017

Gastroparesis:

American College of Gastroenterology, “Clinical Guideline: Management of Gastroparesis,” November 2012

Administration: Oral

In GI motility disorders, administer 15 to 30 minutes prior to meals and at bedtime if needed.

Storage/Stability

Store at room temperature of 15°C to 30°C (59°F to 86°F). Protect from light and moisture.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat a slow moving GI (gastrointestinal) tract in some people.

• It is used to prevent upset stomach and throwing up caused by drugs used for Parkinson's disease.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Headache

• Dry mouth

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Fast or abnormal heartbeat

• Chest pain or pressure

• Dizziness or passing out

• Enlarged breasts, nipple discharge, not able to get or keep an erection (in males), or period (menstrual) changes (in females)

• Lump in breast or breast soreness

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Medication Safety Issues

​Sound-alike/look-alike issues:

​Other safety concerns:

Prescribing and Access Restrictions

Domperidone is available via an Investigational New Drug Application (IND) in the United States for severe GI disorders refractory to standard therapy. For more information on the requirements for the IND, contact the Food and Drug Administration (FDA) at 301-796-3400.

Contraindications

Hypersensitivity to domperidone or any component of the formulation; prolactin-releasing pituitary tumor (prolactinoma); known existing prolongation of cardiac conduction intervals, particularly QT; significant electrolyte disturbances; underlying cardiac disease (eg, heart failure); moderate or severe hepatic impairment; patients with GI hemorrhage, mechanical obstruction, or perforation; concomitant use with potent CYP3A4 inhibitors such as azole antifungals (eg, ketoconazole), macrolides (eg, erythromycin), protease inhibitors, or nefazodone; concomitant use with QT-prolonging drugs

Warnings/Precautions

Concerns related to adverse effects:

• Altered cardiac conduction: [Canadian Boxed Warning]: Domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death, particularly with doses >30 mg or when used in patients >60 years of age. Use the lowest possible dose for the shortest duration necessary. Do not exceed 30 mg/day. Avoid use of domperidone for the following: concomitant use of drugs which prolong the QTc interval and with potent CYP3A4 inhibitors which may increase domperidone exposure, existing prolongation of cardiac conduction intervals (particularly QT), significant electrolyte disturbances or underlying cardiac diseases (eg, heart failure). QTc prolongation, life-threatening tachyarrhythmias (eg, torsade de pointes), and cardiac arrest have been reported after use; these adverse effects may be precipitated in patients with preexisting prolonged cardiac conduction or other underlying cardiac disease, hypokalemia, or receiving other QTc-prolonging agents. The American College of Gastroenterology guidelines recommend baseline and follow-up ECGs and avoiding use if corrected QT is >450 msec in male patients or >470 msec in female patients (Arnold 2013; Camilleri 2013).

• Elevated prolactin levels: May increase prolactin levels (dose-dependent response); may be asymptomatic (clinical consequence of chronically-elevated prolactin is unknown) or may present symptomatically as galactorrhea, gynecomastia, amenorrhea, or impotence (reversible upon decreasing dose or discontinuing drug). Use is contraindicated in patients with prolactinomas.

Disease-related concerns:

• Breast cancer: Use caution when administering to patients with a personal or family history of breast cancer; evidence regarding an association between chronic use of dopamine-receptor antagonists and breast cancer is limited and nonconclusive.

• Hepatic impairment: Undergoes extensive hepatic metabolism; use is contraindicated in patients with moderate to severe hepatic impairment; use with caution in mild impairment.

• Renal impairment: Use with caution in patients with severe renal impairment; dosage and/or frequency of administration may need adjusted with repeated use and/or long-term therapy. Monitor renal function regularly, particularly with long-term therapy.

Other warnings/precautions:

• Breast milk production stimulant: In 2004, the Food and Drug Administration (FDA) issued a warning recommending that domperidone not be used off-label to increase milk production in breast-feeding women due to safety concerns. Several cases of cardiac arrhythmia, cardiac arrest, and sudden death have been reported in patients receiving intravenous domperidone. The risk of similar adverse events in breast-feeding women is unknown. Domperidone is not available for any use in the United States (except via severe GI disorder IND) and does not have approval for this indication in other countries.

Pregnancy Considerations

Information related to use in pregnancy is limited. A single prospective study of 120 cases did not identify an increased risk of adverse events; effects on maternal or fetal cardiac function were not evaluated (Choi 2013).

Breast-Feeding Considerations

Domperidone is present in breast milk. Breastfeeding is not recommended by the manufacturer.

The relative infant dose (RID) of domperidone is 0.12% when calculated using a median breast milk concentration from a single study and compared to a weight-adjusted maternal dose of 20 mg three times a day.

In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).

The RID of domperidone was calculated using a median milk concentration of 6.9 ng/mL, providing an estimated daily infant dose via breast milk of 0.001 mg/kg/day. This milk concentration was obtained following maternal administration of oral domperidone 20 mg three times a day for 10 to 15 days; women in the study (n=7) were between 14 and 21 days' postpartum and gave birth to premature infants. Breast milk was obtained 3 hours after the maternal dose and represented peak concentrations (Knoppert 2013).

Domperidone may increase prolactin concentrations and cause galactorrhea and gynecomastia. As such, it has been used off-label as a galactagogue in patients with insufficient milk production. Pooled data from the limited available studies note milk production may be increased over placebo; adverse events were not reported in breastfeeding infants (Grzeskowiak 2018; Paul 2015; Osadchy 2012; Taylor 2019).

[Canadian Boxed Warning]: Domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death, particularly with doses >30 mg.

Domperidone is not currently approved in any country as a galactagogue (Sewell 2017). The US Food and Drug Administration (FDA) has issued a warning recommending that domperidone not be used off-label to increase milk production in breastfeeding women due to safety concerns related to cardiac arrhythmias, cardiac arrest, and sudden death (FDA 2004). In Canada where omperidone is approved for other indications, a maximum daily dose has been recommended to decrease the incidence of abnormal heart rhythms and cardiac arrest (Health Canada 2015); some studies evaluating domperidone off-label as a galactagogue have used doses higher than the maximum recommended labeled indication (Jantarasaengaram 2012; Knoppert 2013). Adverse cardiac events have been reported following maternal use for lactation enhancement; QT prolongation has also been observed in infants treated with domperidone (Sewell 2017). The risk of adverse cardiac events may be increased in women with a history of arrythmias or those using concomitant medications which may inhibit the metabolism of domperidone (Brodribb [ABM 2018]). Psychiatric symptoms, including insomnia and anxiety/panic attacks were reported in two women 1 to 2 weeks after discontinuing domperidone (Doyle 2018; Papastergiou 2013).

Due to the potential for adverse maternal events, a full evaluation for medical causes of low milk supply and nonpharmacologic measures should be considered prior to the use of medications as galactagogues. The Academy of Breastfeeding Medicine (ABM) does not recommend use of any specific galactagogue due to inconclusive data and potential adverse effects. If use of domperidone is being considered, women should be screened for a history of cardiac arrythmias and concurrent use of medications that may increase the risk of arrythmias. An electrocardiogram prior to use and 48 hours after domperidone is initiated may be considered for some women. Various doses and durations of therapy have been suggested; generally, the maximum effect is observed by 7 to 14 days. The lowest possible dose for the shortest duration of time is recommended. In addition, consider a gradual discontinuation of domperidone (Brodribb [ABM 2018]).

Adverse Reactions

1% to 10%:

Central nervous system: Headache (≤1%), migraine (≤1%)

Gastrointestinal: Xerostomia (2%)

<1%, postmarketing, and/or case reports: Abdominal cramps, acid regurgitation, change in appetite, conjunctivitis, constipation, diarrhea, dizziness, dysuria, edema, extrapyramidal reaction (rare), galactorrhea, gynecomastia, heartburn, hot flash, increased serum ALT, increased serum AST, increased serum cholesterol, increased serum prolactin, increased thirst, insomnia, irritability, leg cramps, lethargy, mastalgia, menstrual disease, nausea, nervousness, palpitations, pruritus, skin rash, stomatitis, torsades de pointes, urinary frequency, urticaria, weakness

Toxicology

• Metoclopramide and Related Agents

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP2B6 (minor), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions Open Interactions

Abametapir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Anticholinergic Agents: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Domperidone. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Exceptions: Crizotinib; Dronedarone; Erythromycin (Systemic); Fluconazole; Nilotinib; Ribociclib. Risk X: Avoid combination

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Domperidone. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Exceptions: Ceritinib; Clarithromycin; Saquinavir; Voriconazole. Risk X: Avoid combination

Erdafitinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Fexinidazole [INT]: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk). Risk X: Avoid combination

Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Fosfomycin: Gastrointestinal Agents (Prokinetic) may decrease the serum concentration of Fosfomycin. Risk C: Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Haloperidol: May enhance the QTc-prolonging effect of Domperidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Larotrectinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Lefamulin: May enhance the QTc-prolonging effect of QT-prolonging CYP3A4 Substrates. Management: Do not use lefamulin tablets with QT-prolonging CYP3A4 substrates. Lefamulin prescribing information lists this combination as contraindicated. Risk X: Avoid combination

Levosulpiride: Benzamide Derivatives may enhance the adverse/toxic effect of Levosulpiride. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Risk C: Monitor therapy

Ondansetron: Domperidone may enhance the QTc-prolonging effect of Ondansetron. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Opioid Agonists: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Pentamidine (Systemic): Domperidone may enhance the QTc-prolonging effect of Pentamidine (Systemic). Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk D: Consider therapy modification

Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk). Risk X: Avoid combination

Posaconazole: May increase the serum concentration of QT-prolonging CYP3A4 Substrates. Such increases may lead to a greater risk for proarrhythmic effects and other similar toxicities. Risk X: Avoid combination

QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of Domperidone. Risk X: Avoid combination

QT-prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of Domperidone. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk. Exceptions: Ceritinib; Clarithromycin; Crizotinib; Erythromycin (Systemic); Fluconazole; Nilotinib; Pimozide; Ribociclib; Saquinavir; Voriconazole. Risk D: Consider therapy modification

QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Domperidone may enhance the QTc-prolonging effect of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone. Risk X: Avoid combination

QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of Domperidone. QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of Domperidone. Risk X: Avoid combination

Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Sirolimus: Gastrointestinal Agents (Prokinetic) may increase the serum concentration of Sirolimus. Risk C: Monitor therapy

Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring. Risk D: Consider therapy modification

Food Interactions

Domperidone serum concentrations may be increased when taken with grapefruit juice. Management: Avoid concurrent use.

Genes of Interest

• Cytochrome P450 3A4
• Potassium Voltage-Gated Channel, Isk-Related Family, Member 1
• Voltage-Gated Sodium Channel 5A

Monitoring Parameters

Renal function; ECG (baseline and then periodically during therapy)

Product Availability

Not available in the US

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 10 mg

Anatomic Therapeutic Chemical (ATC) Classification

• A03FA03

Generic Available (US)

May be product dependent

Mechanism of Action

Domperidone has peripheral dopamine receptor blocking properties and does not readily cross the blood-brain barrier. It increases esophageal peristalsis and increases lower esophageal sphincter pressure, increases gastric motility and peristalsis, and enhances gastroduodenal coordination, therefore, facilitating gastric emptying and decreasing small bowel transit time.

Pharmacodynamics/Kinetics

Protein binding: 93%

Metabolism: Hepatic via CYP3A4, N-dealkylation and hydroxylation

Half-life elimination: 7 hours (increases to ~21 hours in severe renal impairment)

Time to peak serum concentration: 30 minutes

Excretion: Feces (66%); urine (31%)

Local Anesthetic/Vasoconstrictor Precautions

Domperidone is one of the drugs confirmed to prolong the QT interval and is accepted as having a risk of causing torsade de pointes. The risk of drug-induced torsade de pointes is extremely low when a single QT interval prolonging drug is prescribed. In terms of epinephrine, it is not known what effect vasoconstrictors in the local anesthetic regimen will have in patients with a known history of congenital prolonged QT interval or in patients taking any medication that prolongs the QT interval. Until more information is obtained, it is suggested that the clinician consult with the physician prior to the use of a vasoconstrictor in suspected patients, and that the vasoconstrictor (epinephrine, mepivacaine and levonordefrin [Carbocaine® 2% with Neo-Cobefrin®]) be used with caution.

Dental Health Professional Considerations

Domperidone is known to prolong the QT interval. The QT interval is measured as the time and distance between the Q point of the QRS complex and the end of the T wave in the ECG tracing. After adjustment for heart rate, the QT interval is defined as prolonged if it is more than 450 msec in men and 460 msec in women. A long QT syndrome was first described in the 1950s and 60s as a congenital syndrome involving QT interval prolongation and syncope and sudden death. Some of the congenital long QT syndromes were characterized by a peculiar electrocardiographic appearance of the QRS complex involving a premature atria beat followed by a pause, then a subsequent sinus beat showing marked QT prolongation and deformity. This type of cardiac arrhythmia was originally termed “torsade de pointes” (translated from the French as “twisting of the points”). Domperidone is considered as having a risk of causing torsade de pointes. Since it is not known what effect vasoconstrictors in the local anesthetic regimen will have in patients with a known history of congenital prolonged QT interval or in patients taking any medication that prolongs the QT interval, a medical consult is suggested.

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Drug-Induced Prolongation of the QT Interval and Torsades de Pointes
• Relative Infant Dose

Index Terms

Domperidone Maleate

References

Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52.[PubMed 27060684]

Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2015.

Arnold G, Beaves M. Update on clinical guidelines for the management of gastroparesis. Am J Gastroenterol. 2013;108(9):1538-1539.[PubMed 24005360]

Brodribb W. ABM Clinical protocol #9: use of galactogogues in initiating or augmenting maternal milk production, second revision 2018. Breastfeed Med. 2018;13(5):307-314. doi:10.1089/bfm.2018.29092.wjb[PubMed 29902083]

Camilleri M, Parkman HP, Shafi MA, et al, “Clinical Guideline: Management of Gastroparesis,” Am J Gastroenterol, 2013, 108(1):18–37.[PubMed 23147521]

Choi JS, Han JY, Ahn HK, et al. Fetal and neonatal outcomes in women taking domperidone during pregnancy. J Obstet Gynaecol. 2013;33(2):160-162.[PubMed 23445139]

da Silva OP, Knoppert DC, Angelini MM, et al, “Effect of Domperidone on Milk Production in Mothers of Premature Newborns: A Randomized, Double-Blind, Placebo-Controlled Trial,” CMAJ, 2001, 164(1):17-21.[PubMed 11202662]

Doyle M, Grossman M. Case report: domperidone use as a galactagogue resulting in withdrawal symptoms upon discontinuation. Arch Womens Ment Health. 2018;21(4):461-463. doi:10.1007/s00737-017-0796-8[PubMed 29090362]

Drolet B, Rousseau G, Daleau P, et al, “Domperidone Should Not be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders,” Circulation, 2000, 102(16):1883-5.[PubMed 11034933]

Dumitrascu DL and Weinbeck M, “Domperidone Versus Metoclopramide in the Treatment of Diabetic Gastroparesis,” Am J Gastroenterol, 2000, 95(1):316-7.[PubMed 10638616]

“FDA Warns Against Women Using Unapproved Drug, Domperidone, to Increase Milk Production.” Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154914.htm

Grzeskowiak LE, Smithers LG, Amir LH, Grivell RM. Domperidone for increasing breast milk volume in mothers expressing breast milk for their preterm infants: a systematic review and meta-analysis. BJOG. 2018;125(11):1371-1378. doi:10.1111/1471-0528.15177[PubMed 29469929]

Health Canada. Summary Safety Review. DOMPERIDONE. Serious abnormal heart rhythms and sudden death (cardiac arrest), January 27, 2015. Available at https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43423a-eng.php#

Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126.[PubMed 10891521]

Jantarasaengaram S, Sreewapa P. Effects of domperidone on augmentation of lactation following cesarean delivery at full term. Int J Gynaecol Obstet. 2012;116(3):240-243. doi:10.1016/j.ijgo.2011.10.019[PubMed 22189066]

Knoppert DC, Page A, Warren J, et al. The effect of two different domperidone doses on maternal milk production. J Hum Lact. 2013;29(1):38-44.[PubMed 22554679]

Osadchy A, Moretti ME, Koren G. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int. 2012;2012:642893.[PubMed 22461793]

Paul C, Zénut M, Dorut A, et al. Use of domperidone as a galactagogue drug: a systematic review of the benefit-risk ratio. J Hum Lact. 2015;31(1):57-63.[PubMed 25475074]

Papastergiou J, Abdallah M, Tran A, Folkins C. Domperidone withdrawal in a breastfeeding woman. Can Pharm J (Ott). 2013;146(4):210-212. doi:10.1177/1715163513492928

Sewell CA, Chang CY, Chehab MM, Nguyen CP. Domperidone for lactation: what health care providers need to know. Obstet Gynecol. 2017;129(6):1054-1058.[PubMed 28486375]

Taylor A, Logan G, Twells L, Newhook LA. Human milk expression after domperidone treatment in postpartum women: a systematic review and meta-analysis of randomized controlled trials. J Hum Lact. 2019;35(3):501-509. doi:10.1177/0890334418812069[PubMed 30481478]

Brand Names: International

Agilam (VE); Almedon (PK); Amistop (BH); Apildon (HK); Bropasmo (PY); Brulium (UA); Cilroton (GR); Costi (TW); Costil (ID); Dany (TH); Dispel (PH); Domerdon (TH); Domerid (IE, MT); Dometa (ID); Domidon (UA); Domigest (EG); Domne (MY); Domp (BD); Domp-M (TH); Dompe (TW); Domper (MY, PH, TW); Domperid (CN); Domperine (KR); Dompidone (EG); Dompil (VN); Dompy (AE, BH, QA); Domrid (UA); Domstal (IN, ZW); Don-A (PH); Dosin (CL); Emelium (LK); Gasdol (CL); Gasidone (PH); Gastroflux (GT); Gastromotil (EG); Gerdilium (ID); GI Norm (PH); Hamidon (KR); Harmetone (CO); Idon (PE, PY); Mocydone M (TH); Mododom (AE, LB, QA); Modomed (TH); Mogasinte (PT); Motidone (MY); Motigut (MY); Motilat (JO, LB); Motilia (PH); Motilium (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CN, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FR, GB, GT, GY, HK, HN, HU, ID, IE, IL, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NZ, PA, PE, PH, PK, PR, PT, PY, QA, RO, RU, SG, SR, SV, TR, TT, TW, UA, UY, VN, ZA, ZW); Motilium [tabs.] (PL); Motinorm (IN, PH); Mutilium (SA); Nauzelin (ES, JP); Netaf (PE); Nidolium (TW); Ninlium (TH); Nordonil (PT); Oroperidys (FR); Pepridon (PH); Peptomet (BH, CY); Peridon (IT, JO); Peridone (LK); Peridys (FR); Prevomit FT (VN); Prokinin (QA); Rabugen (MY); Rabugen-M (HK, MY); Remotil (PT); Seronex (CR, DO, GT, HN, MX, NI, PA, SV); Siligaz (CL); Smood (MY); Stopvom (IN); Tametil (HR); Tilidon (ID); Vave (BD); Vemetis-10 (HK); Vometa (ID, PH); Vometa FT (LK, MY); Vomitil (PK); Vomitil-M (TH); Weitul (TW); Xepadon (BD); Yaridon (ID); Zidon-DT (IN); Zilium (BE); Zydom (PH)

Last Updated 9/23/20